Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens

2nd June 2026 Uncategorised 0

As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for COVID-19 under an emergency use authorization during the pandemic.

More: Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens
Source: fierce